KUMASHIRO Naoki

■FacultyDepartment of Diabetology and Endocrinology
■PositionProfessor

Researcher Profile & Settings

Research

    Overview of research:
    We promote basic and clinical research to help diabetic patients lead a life equivalent to a non-diabetic person. We will advocate for early therapeutic intervention to prevent cardiovascular and microvascular complications. In consideration of an aging society, we will also be aware of measures to combat complications of sarcopenia and other geriatric syndromes. We also aim to preserve and improve patients' quality of life. As for research methods, continuing basic research using conventional mice and cells is essential, and we will actively conduct human studies to build evidence useful in daily clinical practice. In this process, we will apply various advanced clinical examination techniques and make full use of data analysis using digital devices and artificial intelligence.

Research Activities

Published Papers

  • Empagliflozin reduces liver fibrosis by restoring catechol-O-methyltransferase activity associated with magnesium levels, (Yoshihiro Hayashi), Emi Kawakita, Naoki Kumashiro, Hiroshi Iijima, Daisuke Koya, Keizo Kanasaki, Scientific reports, 15:27310:doi: 10.1038/s41598-025-12813-x, Jul. 2025
  • Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study, Yasutaka Takeda, (Masato Furuhashi), Ichiro Sakuma, Shinya Hiramitsu, Mizuho Okada, Shinichiro Ueda, Naoki Kumashiro, Masaru Sakurai, Frontiers in endocrinology, 16:1549687:doi: 10.3389/fendo.2025.1549687. eCollection 2025, May 2025
  • Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study, (Kota Takuma),(Ayako Fuchigami), Fumika Shigiyama, Naoki Kumashiro, Takahisa Hirose, Diabetes, Obesity and Metabolism, 25:2131-2141, Aug. 2023
  • Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: a prospective randomized study, (Shigenori Hiruma), Fumika Shigiyama, Naoki Kumashiro, Diabetes, Obesity and Metabolism, 25:1576-1588, Jun. 2023
  • Capivasertib-induced diabetes successfully managed with insulin-independent glucose-Lowering agents: a case report, Yasutaka Takeda, Mariko Tsuyama, Yusuke Haba, Masafumi Inokuchi, Naoki Kumashiro, Cureus, 18:e105623, Mar. 2026
  • Impact of Elovl3 suppression on sleep deprivation-induced hepatic steatosis and glucose intolerance in mice, Fumika Shigiyama, Sayaka Tanaka, Chiaki Okayama, Naoki Kumashiro, 18:e107228, Apr. 2026